genOway
Sarah Duponchel is an experienced researcher and manager in the field of gene editing, currently serving as R&D manager and senior scientist at genOway since April 2021. Prior to this, Sarah held positions at the Max Planck Institute for Medical Research as a researcher in virology from August 2017 to April 2021, and at INSERM as a chargé d'étude en virologie where the focus was on the interactions between cells and pathogens during hepatitis C virus infection from October 2013 to June 2017. Earlier career experiences include work as a jeune chercheur at UPMC - Sorbonne Universities from October 2010 to September 2013, where Sarah generalized a reverse genetics system for rotavirus and studied interactions between autophagy and rotavirus. Sarah also served as a chargé de travaux dirigés, providing annual applied methodology sessions in life sciences. Sarah holds a Ph.D. in molecular and cellular biology with a focus on virology from Pierre and Marie Curie University, alongside a master's degree in virology and a Licence 3 in biology and genetics from Bucknell University.
This person is not in any teams
This person is not in any offices
genOway
1 followers
Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of unique, innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research. Based on its core business and leading expertise in custom-designed models, the company invests in cancer research, with a growing catalog of currently over 30 translational models for immuno-oncology and immunotherapy. genOway holds all relevant licenses on patented technologies used for its model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9 patents portfolio, which enables the company to guarantee its clients FTO, freedom to operate. Headquartered in Lyon, France, genOway serves clients in 380 academic institutions and 170 life sciences companies, including 17 of the top 20 pharma.